They are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Their mission is to expand the reach of targeted therapeutics by developing products for underserved populations. They utilize their deep expertise in structure-based drug discovery, translational research and patient-driven precision medicine, which they collectively refer to as their Kinnate Discovery Engine, to develop their targeted therapies. They focus their discovery and development efforts on three patient populations: (1) those with cancers that harbor known oncogenic drivers (gene mutations that cause cancers) with no currently available targeted therapies, (2) those with genomically well-characterized tumors that have intrinsic resistance to currently available treatments, and (3) those whose tumors have acquired resistance over the course of therapy to currently available treatments. They believe their unique approach may enable them to develop drugs with an increased probability of clinical success while reducing the cost and risk of drug development.